WASHINGTON, December 28, 2025 – A pill form of Wegovy, a popular weight-loss drug, was approved by the Food and Drug Administration on December 22.It offers a convenient alternative to weekly injections.
Pill Power: A New Era for Weight Loss Drugs?
Table of Contents
The FDA approval coudl increase access to GLP-1 medications, though cost remains a factor.
- The FDA approved a pill version of Wegovy on December 22.
- Studies show the pill is as effective as the injectable for weight loss.
- Prices range from $150-$400 monthly, starting January 5.
- Eli Lilly expects to seek approval for a competing pill this year.
The Wegovy pill contains semaglutide,also found in Ozempic. Research indicates similar weight-loss efficacy compared to injections.
Pricing-The pill starts at $150, with higher doses costing up to $400 monthly, effective January 5. Insurance co-pays may be as low as $25.
Affordability-Competition and compounded versions are lowering GLP-1 prices.
The Rise of Compounded Alternatives
Compounded versions, made by specialized pharmacies, offer lower-priced alternatives due to shortages of brand-name drugs. Novo Nordisk and Eli Lilly have responded with discounts.
Discounts from manufacturers followed the rise of compounding pharmacies.
Insurance Coverage: A Elaborate Landscape
coverage-Insurance coverage is frequently enough limited to those with a BMI of 40 or higher, despite obesity being defined as a BMI of 30. Broader coverage is absolutely possible with ongoing studies in 2026.